Alyeska Investment Group
TCON

Alyeska Investment Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Alyeska Investment Group’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-500
Closed -$270K – 530
2018
Q2 		$270K Buy
500
+16
+3% +$8.51K ﹤0.01% 437
2018
Q1 		$223K Sell
484
-4
-0.8% -$2.18K ﹤0.01% 432
2017
Q4 		$327K Hold
488
– – ﹤0.01% 414
2017
Q3 		$308K Buy
488
+8
+2% +$4.17K ﹤0.01% 446
2017
Q2 		$230K Sell
480
-14
-3% -$8.54K ﹤0.01% 440
2017
Q1 		$371K Sell
494
-6
-1% -$5.38K ﹤0.01% 458
2016
Q4 		$490K Buy
+500
New +$571K ﹤0.01% 447

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alyeska Investment Group's TCON Position: Q3 2018 in Review

Alyeska Investment Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2018, closing a stake of 500 shares — an estimated $270K sold.

Alyeska Investment Group first reported a position in TCON in Q4 2016 and held it in 7 quarters. The position peaked at $490K in Q4 2016. 37 funds tracked by Wall St. Rank hold TCON as of Q3 2018.

  • Alyeska Investment Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 500 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $270K.
  • Alyeska Investment Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 7 quarters.
  • Alyeska Investment Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $490K in Q4 2016.
  • 37 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.